Dose Determination of Taxotere, Eloxatin and Xeloda (TEX) in Combination With Herceptin as First-line Treatment for Patients With HER2 Positive Non-resectable Oesophagus, Cardia or Gastric Cancer (ECV).

Trial Profile

Dose Determination of Taxotere, Eloxatin and Xeloda (TEX) in Combination With Herceptin as First-line Treatment for Patients With HER2 Positive Non-resectable Oesophagus, Cardia or Gastric Cancer (ECV).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2015

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Acronyms Her-TEX
  • Most Recent Events

    • 19 Feb 2011 New trial record
    • 14 Jan 2011 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top